Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
BioLife Solutions, Inc. furnished a current report to disclose that on January 12, 2026 it issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1, and the company states that this revenue information and the exhibit are being furnished, not filed, so they are not subject to certain liability provisions and are not automatically incorporated into other securities law filings.
BioLife Solutions, Inc. reports that its Chief Quality and Operations Officer, Karen Foster, has decided to retire. She provided notice of her decision on January 8, 2026, and her retirement will be effective March 31, 2026. The company states that her decision to retire is not due to any disagreement with BioLife Solutions on operations, policies, or practices. The company also expresses appreciation for her service and extends best wishes for her retirement.
BioLife Solutions Chief Financial Officer Troy Wichterman reported selling 990 shares of common stock on 01/06/2026 at $25.59 per share. Following this sale, he beneficially owned 150,746 shares.
The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 to satisfy tax withholding obligations arising from the vesting of restricted stock, indicating it was linked to equity compensation rather than a discretionary open-market exit.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations Officer, reported a small automatic sale of company stock. On 01/06/2026, she sold 335 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, she beneficially owned 191,984 shares of common stock directly. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023 and was used to cover tax withholding obligations tied to the vesting of restricted stock.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a small sale of company stock. On 01/06/2026, she sold 241 shares of Common Stock at a price of $25.59 per share, leaving her with 75,765 shares owned directly after the transaction.
According to the footnote, this sale was made under a Rule 10b5-1(c) trading plan that was adopted effective 01-03-2023. The filing explains that the trade was executed to satisfy tax withholding obligations related to the vesting of restricted stock rather than as a discretionary open-market sale.
BioLife Solutions executive Aby J. Mathew reported a small insider sale of company stock. On 01/06/2026, the EVP & Chief Scientific Officer sold 405 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, he directly held 349,350 shares of the company’s common stock.
The sale was made under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023, and was carried out to satisfy tax withholding obligations arising from the vesting of restricted stock.
BioLife Solutions' Chief Marketing Officer reported a small insider sale of company stock. On 01/06/2026, Todd Berard sold 344 shares of BioLife Solutions common stock at a price of $25.59 per share, leaving him with 132,564 shares beneficially owned directly after the transaction.
According to the disclosure, this sale was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 and was executed to satisfy tax withholding obligations related to the vesting of restricted stock. This indicates the transaction was part of tax and compensation administration rather than a discretionary open-market sale.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,180,824 shares of BioLife Solutions Inc. common stock, representing 10.8% of the class as of December 31, 2025. The firm has sole power to vote and dispose of all reported shares, with no shared voting or dispositive power.
The filer is classified as an investment adviser and states that the shares were acquired and are held in the ordinary course of business. It also certifies that the holdings are not intended to change or influence control of BioLife Solutions and expressly denies being the beneficial owner of the securities beyond what is required for reporting.
BioLife Solutions Inc. executive vice president and chief scientific officer Aby J. Mathew reported a small insider sale of company stock. On 12/09/2025, he sold 631 shares of common stock at $25.13 per share. After this transaction, he directly owns 349,755 shares of BioLife Solutions common stock.
The filing states that this sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, which was adopted effective 03-08-2024. The purpose of the plan was to sell shares to cover tax withholding obligations arising from the vesting of restricted stock, indicating this was an automated, tax-related transaction rather than a discretionary open-market sale.
BioLife Solutions Inc.'s Chief Financial Officer reported a sale of company stock under a pre-arranged Rule 10b5-1(c) trading plan. On 12/09/2025, the officer sold 1,033 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 151,736 shares of BioLife Solutions common stock in direct ownership. The filing explains that the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
